plerixafor has been researched along with Cognitive Dysfunction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boltze, J; Campos, RMP; Conde, L; Didwischus, N; Mendez-Otero, R; Pimentel-Coelho, PM; Spiess, DA | 1 |
| Barbiro, B; Ezra, A; Gavriel, Y; Rabinovich-Nikitin, I; Solomon, B | 1 |
2 other study(ies) available for plerixafor and Cognitive Dysfunction
| Article | Year |
|---|---|
Subacute AMD3100 Treatment Is Not Efficient in Neonatal Hypoxic-Ischemic Rats.
Topics: Animals; Animals, Newborn; Atrophy; Benzylamines; Brain; Cognitive Dysfunction; Cyclams; Endpoint Determination; Female; Hypoxia-Ischemia, Brain; Male; Maze Learning; Pregnancy; Psychomotor Performance; Rats; Rats, Wistar; Receptors, CXCR4; Sex Characteristics; Treatment Failure | 2022 |
Subcutaneous Administration of AMD3100 into Mice Models of Alzheimer's Disease Ameliorated Cognitive Impairment, Reduced Neuroinflammation, and Improved Pathophysiological Markers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-HIV Agents; Benzylamines; Biomarkers; Cognitive Dysfunction; Cyclams; Disease Models, Animal; Inflammation; Inflammation Mediators; Injections, Intraventricular; Injections, Subcutaneous; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptide Fragments | 2020 |